Trial Profile
A Phase 1 Study of rSIFN-co for Subjects With Advanced Solid Tumors Where Interferons Are Known to Have Demonstrated Antitumor Activity
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Jun 2022
Price :
$35
*
At a glance
- Drugs RSIFN-co (Primary)
- Indications Carcinoma; Colorectal cancer; Lung cancer; Malignant melanoma; Neuroendocrine carcinoma; Prostate cancer; Renal cancer; Solid tumours
- Focus Adverse reactions
- Acronyms EffTox
- Sponsors Sichuan Huiyang Life Science and Technology Corporation
- 16 Jun 2022 Planned End Date changed from 1 Dec 2022 to 1 Jun 2024.
- 16 Jun 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2023.
- 17 Mar 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.